Can You Stop Myeloma Treatment and Still Stay in Remission?

Event Description
Join us for an insightful webinar with Dr. Samer Al Hadidi as he discusses the evolving role of fixed duration treatment in multiple myeloma. For many years, treatment has continued indefinitely—until relapse or intolerable side effects. But emerging research is challenging that standard. Dr. Al Hadidi will share insights from his ongoing studies, exploring how deeper, more durable responses may allow some patients to safely pause treatment. Learn what this shift could mean for your care and the future of myeloma therapy.
Schedule & Agenda

Cynthia introduces the agenda of the event and featured speaker Samer Al Hadidi, M.D., M.S.(CRDSA), FACP

Cynthia introduces the agenda of the event and featured speaker Samer Al Hadidi, M.D., M.S.(CRDSA), FACP

Dr. Hadidi talks about stopping myeloma treatment and remission

Dr. Hadidi talks about stopping myeloma treatment and remission
Type your questions in the chat and we will answer them!
Type your questions in the chat and we will answer them!
Speakers & Moderators

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.

Samer Al Hadidi, M.D., M.S.(CRDSA), FACP, is an associate professor of Medicine. He earned his medical degree from University of Jordan, and his M.S.(CRDSA) at the School of Public Health and Biostatistics at the University of Michigan-Ann Arbor. Dr. Al Hadidi trained in Internal Medicine in Hurley Medical Center/Michigan State University and Hematology & Oncology in Baylor College of Medicine. Dr. Al Hadidi is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the American Society for Transplantation and Cellular Therapy (ASTCT). Dr. Al Hadidi research interests include plasma cell dyscrasias including multiple myeloma with a focus on drug development, cellular therapy, immunotherapy, health equity and medical education.
Join the Conversation
This event is part of the Treatments & Drugs group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org

Get the Latest Blood Cancer Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.